Clinical Trial Update: Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain [Phase 2]

View source ↗

Summary

A Phase 2 extension study evaluating ACTIQ for breakthrough pain in children and adolescents has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burns
• Cancer
• Sickle Cell Disease

Drugs mentioned

• Actiq (fentanyl)

Snippet

Sponsor: Cephalon | Conditions: Pain, Cancer | Phase 2 | Status: COMPLETED